Agilent (A) AI Stock Analysis

• Market Cap: $41.37B
• Dividend Yield: 0.72%
• Average Volume (3M): 1.92M
• Price to Earnings (P/E): 31.9
• Beta (1Y): 0.95
• Revenue Growth: 6.73%
• EPS Growth: 3.34%
• Country: US
• Employees: 17,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.59
• Shares Outstanding: 283,498,870
• 10 Day Avg. Volume: 1,775,850
• 30 Day Avg. Volume: 1,915,546
• PEG Ratio: 9.41
• Price to Book (P/B): 6.14
• Price to Sales (P/S): 5.96
• P/FCF Ratio: 35.95
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 2.44
• Enterprise Value/Gross Profit: 4.67
• Enterprise Value/Ebitda: 9.05
• 1Y Price Target: $167.50
• Price Target Upside: 14.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 5.93
• Revenue Forecast (FY): $7.36B

• Rating: 73 Outperform
• Price Target: $159.00 ▲(8.96% Upside)

Agilent's strong financial performance and positive earnings call guidance are key strengths, supporting a solid overall score. However, technical indicators suggest short-term caution, and the high valuation limits upside potential. Challenges in specific markets and increased tax rates also pose risks.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective product strategies, supporting long-term business expansion.

Innovative Product Launches

Successful new product launches enhance competitive positioning and drive future revenue streams, reinforcing Agilent's market leadership.

Operational Efficiency

Operational efficiencies lead to improved margins, enhancing profitability and providing a buffer against market volatility.

Negative Factors

Decline in Chinese Market

A decline in the Chinese market could hinder growth prospects in a key region, impacting overall revenue potential.

Challenges in Academia and Government Sectors

Reduced spending in academia and government sectors may limit growth opportunities in these segments, affecting long-term diversification.

Increased Tax Rate Impact

Higher tax rates reduce net income, potentially impacting reinvestment capabilities and shareholder returns over the long term.

Agilent Business Overview & Revenue Model

Company Description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

How the Company Makes Money

Agilent generates revenue through a diversified business model primarily focused on three key segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The majority of its income comes from the sale of instruments and consumables, with recurring revenue also derived from services, support, and software subscriptions. Additionally, Agilent benefits from strategic partnerships and collaborations with research institutions and other companies, which enhance its product offerings and expand its market reach. The company's continuous investment in innovation and development of new technologies further contributes to its competitive edge and revenue growth.

Agilent Financial Statement Overview

Summary

Agilent demonstrates strong profitability with healthy margins and stable revenue growth. The balance sheet shows moderate leverage and a solid equity position, although the decline in ROE and free cash flow is a concern.

Income Statement

Agilent demonstrates strong profitability with a consistent gross profit margin above 50% and a net profit margin improving to 23.32% in the latest year. Revenue growth has been modest at 2.36%, indicating stable but slow expansion. EBIT and EBITDA margins are healthy, reflecting efficient operations.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio of 0.50, indicating moderate leverage. Return on equity has decreased to 6.44%, suggesting a decline in profitability relative to equity. The equity ratio remains stable, reflecting a solid financial position.

Cash Flow

Free cash flow has decreased by 17.83%, which is a concern. However, the operating cash flow to net income ratio is strong at 0.66, indicating good cash generation relative to earnings. The free cash flow to net income ratio is also healthy at 0.74.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.95B	6.51B	6.83B	6.85B	6.32B
Gross Profit	3.64B	3.54B	3.46B	3.72B	3.41B
EBITDA	1.83B	1.87B	1.70B	1.91B	1.76B
Net Income	1.30B	1.29B	1.24B	1.25B	1.21B
Balance Sheet
Total Assets	12.73B	11.85B	10.76B	10.53B	10.71B
Cash, Cash Equivalents and Short-Term Investments	1.79B	1.33B	1.59B	1.05B	1.57B
Total Debt	3.35B	3.57B	2.73B	2.77B	2.73B
Total Liabilities	5.99B	5.95B	4.92B	5.23B	5.32B
Stockholders Equity	6.74B	5.90B	5.84B	5.30B	5.39B
Cash Flow
Free Cash Flow	1.15B	1.37B	1.47B	1.02B	1.30B
Operating Cash Flow	1.56B	1.75B	1.77B	1.31B	1.49B
Investing Cash Flow	-394.00M	-1.26B	-310.00M	-338.00M	-749.00M
Financing Cash Flow	-715.00M	-752.00M	-930.00M	-1.37B	-696.00M

Agilent Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 145.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Positive. The current price of 145.92 is above the 20-day moving average (MA) of 141.43, above the 50-day MA of 144.55, and above the 200-day MA of 125.84, indicating a bullish trend. The MACD of 1.10 indicates Negative momentum. The RSI at 53.48 is Neutral, neither overbought nor oversold. The STOCH value of 68.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for A.

Agilent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHR	75 Outperform	$168.08B	48.97	6.84%	0.53%	2.22%	-7.60%
A	73 Outperform	$41.37B	31.92	20.62%	0.72%	6.73%	3.34%
WAT	73 Outperform	$23.41B	36.28	32.99%	―	6.90%	3.86%
IQV	73 Outperform	$41.10B	33.12	19.55%	―	3.85%	-4.74%
TMO	72 Outperform	$233.63B	35.93	13.14%	0.30%	3.22%	8.26%
MTD	64 Neutral	$30.35B	37.33	―	―	4.77%	7.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Agilent Corporate Events

Agilent Appoints Adam S. Elinoff as CFO

On October 23, 2025, Agilent Technologies announced the appointment of Adam S. Elinoff as the new Chief Financial Officer, effective November 17, 2025. Elinoff, who previously held significant finance roles at Amgen, brings extensive experience in corporate finance, strategy, and transformation. His appointment is expected to bolster Agilent’s financial operations and strategic planning as the company aims to accelerate its Ignite Operating System and enhance value creation for customers and shareholders.

The most recent analyst rating on (A) stock is a Hold with a $130.00 price target. To see the full list of analyst forecasts on Agilent stock, see the A Stock Forecast page.